CRIS
Price
$0.43Alerts
Change
-$0.04 (-8.51%)
Updated
Nov 20 closing price
Capitalization
2.2M
115 days until earnings call
Intraday BUY SELL Signals
DMRA
Price
$23.22Alerts
Change
-$1.08 (-4.44%)
Updated
Nov 20 closing price
Capitalization
1.46B
125 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRIS vs DMRA

CRIS vs DMRA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRIS vs. DMRA commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRIS is a Hold and DMRA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRIS with price predictions
Nov 20, 2026

Aroon Indicator for CRIS shows an upward move is likely

CRIS's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 70 similar instances where the Aroon Indicator showed a similar pattern. In 65 of the 70 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +40.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for CRIS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRIS as a result. In 65 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

CRIS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CRIS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.468) is normal, around the industry mean (3.596). P/E Ratio (0.248) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for DMRA with price predictions
Nov 20, 2026

DMRA's RSI Oscillator recovers from oversold territory

The RSI Indicator for DMRA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 25 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

DMRA moved above its 50-day moving average on November 16, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for DMRA crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +7.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMRA advanced for three days, in 207 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

The Aroon Indicator entered an Uptrend today. In 142 of 163 cases where DMRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 48 cases where DMRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DMRA as a result. In 81 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 50-day moving average for DMRA moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

DMRA broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.790) is normal, around the industry mean (3.596). DMRA has a moderately low P/E Ratio (-91.154) as compared to the industry average of (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 31 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DMRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
CRIS vs DMRA: Fundamental Ratings
CRIS
DMRA
OUTLOOK RATING
1..100
4432
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
10031
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6545
P/E GROWTH RATING
1..100
9617
SEASONALITY SCORE
1..100
42n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DMRA's Valuation (2) in the null industry is significantly better than the same rating for CRIS (80) in the Biotechnology industry. This means that DMRA’s stock grew significantly faster than CRIS’s over the last 12 months.

DMRA's Profit vs Risk Rating (31) in the null industry is significantly better than the same rating for CRIS (100) in the Biotechnology industry. This means that DMRA’s stock grew significantly faster than CRIS’s over the last 12 months.

DMRA's SMR Rating (99) in the null industry is in the same range as CRIS (100) in the Biotechnology industry. This means that DMRA’s stock grew similarly to CRIS’s over the last 12 months.

DMRA's Price Growth Rating (45) in the null industry is in the same range as CRIS (65) in the Biotechnology industry. This means that DMRA’s stock grew similarly to CRIS’s over the last 12 months.

DMRA's P/E Growth Rating (17) in the null industry is significantly better than the same rating for CRIS (96) in the Biotechnology industry. This means that DMRA’s stock grew significantly faster than CRIS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRISDMRA
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (CRIS: $0.43 vs. DMRA: $24.30)
Brand notoriety: CRIS and DMRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRIS: 17% vs. DMRA: 83%
Market capitalization -- CRIS: $2.2M vs. DMRA: $1.46B
CRIS [@Biotechnology] is valued at $2.2M. DMRA’s [@Biotechnology] market capitalization is $1.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRIS’s FA Score shows that 0 FA rating(s) are green while DMRA’s FA Score has 3 green FA rating(s).

  • CRIS’s FA Score: 0 green, 5 red.
  • DMRA’s FA Score: 3 green, 2 red.
According to our system of comparison, DMRA is a better buy in the long-term than CRIS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRIS’s TA Score shows that 3 TA indicator(s) are bullish while DMRA’s TA Score has 6 bullish TA indicator(s).

  • CRIS’s TA Score: 3 bullish, 5 bearish.
  • DMRA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DMRA is a better buy in the short-term than CRIS.

Price Growth

CRIS (@Biotechnology) experienced а -4.04% price change this week, while DMRA (@Biotechnology) price change was +10.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

CRIS is expected to report earnings on Mar 16, 2027.

DMRA is expected to report earnings on Mar 25, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

DMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMRA has been loosely correlated with NERV. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if DMRA jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMRA
1D Price
Change %
DMRA100%
-4.44%
NERV - DMRA
45%
Loosely correlated
-5.66%
RANI - DMRA
44%
Loosely correlated
-11.97%
VIVS - DMRA
38%
Loosely correlated
-10.53%
TELO - DMRA
35%
Loosely correlated
-17.24%
XRTX - DMRA
34%
Loosely correlated
-5.73%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SUZ9.10-0.17
-1.83%
Suzano SA
MHH5.89-0.27
-4.46%
Mastech Digital
SGLY0.39-0.02
-5.61%
Singularity Future Technology Ltd
GSM2.12-0.18
-7.63%
Ferroglobe PLC
VECO33.91-3.58
-9.55%
Veeco Instruments